Harpoon Therapeutics Inc

NASDAQ HARP

Data sourced from iex and EODHD
Download Data

Harpoon Therapeutics Inc Liabilities to Equity Ratio 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending September 30, 2023: 247.67%

Harpoon Therapeutics Inc Liabilities to Equity Ratio 1 year YoY Change (%) is 247.67% for the Trailing 12 Months (TTM) ending September 30, 2023, a 222.36% change year over year. The liabilities to equity ratio, also known as the leverage ratio, measures the proportion of a company's total liabilities to its shareholders' equity. It is calculated by dividing the total liabilities by the shareholders' equity. This ratio provides insights into the extent to which a company relies on debt financing compared to equity financing. A higher ratio indicates higher financial leverage, which can amplify both returns and risks for the company's shareholders. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
  • Harpoon Therapeutics Inc Liabilities to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2022 was 2.73, a 76.83% change year over year.
  • Harpoon Therapeutics Inc Liabilities to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2021 was 1.54, a 10.42% change year over year.
  • Harpoon Therapeutics Inc Liabilities to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2020 was 1.40, a 371.27% change year over year.
  • Harpoon Therapeutics Inc Liabilities to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2019 was -0.51, a 73.72% change year over year.
NASDAQ: HARP

Harpoon Therapeutics Inc

CEO Ms. Julie M. Eastland M.B.A.
IPO Date Feb. 8, 2019
Location United States
Headquarters 131 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
Employees 53
Sector Healthcare
Industry Biotechnology
Description

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California. As of March 11, 2024, Harpoon Therapeutics, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.

Similar companies

STOK

Stoke Therapeutics Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email